A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101) Meeting Abstract

  

Authors:	Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; Kroll, K.; Baghaie, S.; Ajmera, A.; Smith, T. J.; Beltran, H.; Chen, R. C.; McKay, R. R.; Galsky, M. D.; Rosenberg, J. E.; Morris, M. J.
Abstract Title:	A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)
Meeting Title:	2024 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	42
Issue:	16 Suppl.
Meeting Dates:	2024 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2024-06-01
Language:	English
ACCESSION:	WOS:001275557406246
PROVIDER:	wos
DOI:	10.1200/JCO.2024.42.16_suppl.TPS5118
Notes:	Meeting Abstract: TPS5118 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/218819